Literature DB >> 7387358

Prognostic value of lymph node dissection in malignant melanoma.

C P Karakousis, M K Seddiq, R Moore.   

Abstract

Retrospective review of 199 patients with malignant melanoma who had regional node dissection showed that the median survival rates of patients with histologically negative nodes was more than threefold higher than that of patients with histologically positive regional nodes. In the patients with positive nodes, survival was related to the number of nodes involved. Patients with one, two, and three or more positive lymph nodes had a tumor-free five-year survival rate of 41%, 30%, and 18%. Patients who required regional node dissection for positive palpable nodes in one month, one year, or longer than one year from the excision of the primary tumor had a median survival of 21.5, 22, and 44 months.

Entities:  

Mesh:

Year:  1980        PMID: 7387358     DOI: 10.1001/archsurg.1980.01380060021006

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  11 in total

1.  A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate.

Authors:  W A Cassel; D R Murray
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

2.  The prognosis of melanoma patients with metastases to two or more lymph node areas.

Authors:  R J Barth; D J Venzon; A R Baker
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

3.  British Association of Clinical Anatomists: Abstracts of papers presented at the Annual General Meeting on 11th January 1985 at The Queen Elizabeth Postgraduate Centre, University of Birmingham.

Authors: 
Journal:  Ann R Coll Surg Engl       Date:  1986-03       Impact factor: 1.891

4.  Frequency of occult residual melanoma after excision of a clinically positive regional lymph node.

Authors:  M Kane; E McClay; R E Bellet
Journal:  Ann Surg       Date:  1987-01       Impact factor: 12.969

Review 5.  Management of the regional lymph nodes in patients with cutaneous malignant melanoma.

Authors:  A J Cochran; D R Wen; D L Morton
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

6.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

7.  [Surgical treatment of malignant melanomas of the skin].

Authors:  L Lukács; S Péter
Journal:  Langenbecks Arch Chir       Date:  1984

8.  Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis.

Authors:  D G Coit; A Rogatko; M F Brennan
Journal:  Ann Surg       Date:  1991-11       Impact factor: 12.969

9.  Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes.

Authors:  C Callery; A J Cochran; D J Roe; W Rees; S D Nathanson; J K Benedetti; R M Elashoff; D L Morton
Journal:  Ann Surg       Date:  1982-07       Impact factor: 12.969

10.  A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II).

Authors:  C M Balch; S J Soong; T M Murad; A L Ingalls; W A Maddox
Journal:  Ann Surg       Date:  1981-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.